Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study.

ABSTRACT:

Background

While apixaban has demonstrated advantages over alternative direct oral anticoagulants (DOACs) in some settings, its comparative safety and effectiveness in cancer-associated venous thromboembolism (VTE) remain uncertain. Current guidelines recommend DOACs as first-line treatment for cancer-associated VTE, though they do not recommend any specific DOAC over another. This study aimed to quantify the risk of recurrent VTE, major bleeding, and clinically relevant non-major bleeding among individuals with cancer-associated VTE treated with apixaban versus rivaroxaban.

Methods and findings

In this retrospective cohort study, we used data from Medicare fee-for-service (2016-2020) and MarketScan (2016-2022), two U.S. administrative claims databases covering publicly and

SUBMITTER: Sun J 

PROVIDER: S-EPMC12494242 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature